Nuclear Medicine Therapy

  In the past one year, the Nuclear Oncology Experts team at the Department of Nuclear Medicine at Fortis Memorial Research Institute has treated 30 new patients of Castrate Resistant Prostate Cancer (CRPC) with  Ac225 PSMA Therapy  (Targeted Alpha Therapy). And the results are similar to the results being achieved by most good Nuclear Medicine Centres across the world – 75-80% of the patients have shown evidence of a significant Radiological and Biochemical Response with prolonged duration of response. ADVERSE EFFECTS: The Ac225 PSMA Therapy is extremely well tolerated with minimal adverse effects that usually do not require any active management. The adverse effects usually experienced are fatigue in the immediate post-therapy, a transient mild drop in blood counts approximately three-weeks post-therapy and dry mouth. SOURCING OF Ac 225: The Ac225 used at the center is a highly purified form with no added carriers. It is approved by the European Medicines Associ...

According to the  World Cancer Research Fund , Prostate Cancer is not only one of the most common malignancy in men but also one of the most commonly occurring cancer overall. Prostate Cancer is also the fifth leading cause of death from cancer in men. Disease progression and metastatic spread signifies the beginning of a lethal form of the disease – metastatic castration resistant prostate cancer (mCRPCa). The incidence of prostate cancer increases proportionally with age, especially in men above 60 years of age. Studies have also shown that incidence of prostate cancer also depend on demographics and racial prevalence – prostate cancer has a low incidence in Asia (3-8 per 100,000 men per year), an intermediate incidence in Africa and Eastern Europe, and a higher incidence in North America and Western Europe. While conventional treatment modalities for localized prostate cancers include surgery, chemotherapy, cryotherapy, brachytherapy with radioactive seeds, and usage of exte...